📅 Posted on September 30, 2024
💡 What’s This About?
A new study examined the combination of two drugs – Eribulin and Carboplatin – in patients with “triple negative” metastatic breast cancer,
where previous treatments failed to stop disease progression.
The study was conducted at several medical centers and evaluated the effectiveness and safety of this drug combination in “real world” conditions 🏥
How Does It Work?
Eribulin is a drug that works by stopping cancer cell division,
and Carboplatin is a chemotherapy drug that damages the DNA of cancer cells.
Their combination is designed to create a stronger effect against the disease 💪
📊 What Did They Find?
The results are particularly encouraging! ✨
* About half of the patients (51.4%) showed a positive response to treatment
* Moreover, 81.1% of patients achieved disease control
* The results were especially good in patients with “triple negative” breast cancer
* The treatment was found to be relatively safe, with manageable side effects 📈
🌟 Why Is This Important?
The study findings offer a promising new treatment option for patients with metastatic breast cancer, especially after previous treatments have failed. This is significant news for many patients seeking additional treatment options! 🙏
Remember, we’re here for you ❤️
Locating and supporting access to innovative drugs and advanced treatments for metastatic and stage 4 cancer patients worldwide 🌍
For more details and to check if we can help in your case >>
https://cancertrialinpharma.ravpage.co.il/Information&Registration 🔍
📲 Share this post – it might help someone you know! 🤝
Yours,
Nir Erez / Trial-In Pharma 👨⚕️
Read the article >>
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study | BMC Cancer | Full Text
